Japan's Astellas Pharma Inc. has announced positive top-line data from the ALPS Phase III study involving the use of the oral investigational agent, roxadustat, in patients with chronic kidney disease (CKD) and anemia not on dialysis, boding well for its use as a therapeutic option in the condition, and for its potential to displace the use of erythropoietin.
The ALPS study found roxadustat showed superiority in efficacy versus placebo in terms of hemoglobin (Hb) response rate in the...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)